论文部分内容阅读
尽管近来有着影象诊断、手术技术及辅助疗法的进展,胰腺腺癌的5年生存率仍小于5%。外科手术是唯一治愈性的疗法,惜在作出诊断时,85%的病例已属晚期。由于缺乏区别正常胰腺细胞和癌细胞的细胞表面的和血清标记物,使胰腺癌的生物学研究受到了阻碍;而单克隆抗体技术的进展,却可能检出很少量的转化或分化抗原。本文作者用胰导管腺癌细胞株(HPAF)作为抗原免疫小鼠,产生了单克隆抗体;经选择后的单克隆抗体和所有受试的胰腺腺癌的各组织成分有反应,和胃癌及胆管癌的反应,以及和正常成人胰腺导管上皮反应百分比也很高,但和其他分泌腺上皮细胞的反应率很低。其中一个单克隆抗体Du-Pan-2对所试验的各
Despite recent advances in imaging diagnosis, surgical techniques, and adjuvant therapies, the 5-year survival rate of pancreatic adenocarcinoma is still less than 5%. Surgery is the only curative therapy, but unfortunately at the time of diagnosis, 85% of cases were already advanced. Because of the lack of cell surface and serum markers that distinguish between normal pancreatic cells and cancer cells, biological studies of pancreatic cancer have been hampered; however, advances in monoclonal antibody technology may detect very few transformed or differentiated antigens. The authors used a pancreatic ductal adenocarcinoma cell line (HPAF) as an antigen to immunize mice and produced monoclonal antibodies; the selected monoclonal antibodies reacted with all tissue components of the pancreatic adenocarcinomas tested, and gastric cancer and bile ducts The reaction rate of cancer, as well as the percentage of normal human adult pancreatic ductal epithelium reaction is also high, but the reaction rate with other secretory glandular epithelial cells is very low. One of the monoclonal antibodies, Du-Pan-2, tested each